| Literature DB >> 28630490 |
Dominik Wodarz1, David N Levy2.
Abstract
A long-lived reservoir of latently infected T cells prevents antiretroviral therapy from eliminating HIV-1 infection. Furthering our understanding of the dynamics of latency generation and maintenance is therefore vital to improve treatment outcome. Using mathematical models and experiments, we suggest that the death of latently infected cells brought about by pyroptosis, or to a lesser extent by superinfection, might be key mechanisms to account for the size and composition of the latent reservoir. Pyroptosis is a form of cell death that occurs in a resting (and thus latently infected) T cell when a productively infected cell attempts cell-to-cell transmission of virus. Superinfection of latently infected cells by productive virus could similarly remove those cells through active virus replication and resulting cytopathicity. The mathematical models presented can explain a number of previously published clinical observations including latent reservoir size and the relationships to viral load in acute HIV infection, measurements of the latent reservoir in chronic infection, and the replacement of wild-type virus by CTL escape mutants within the latent reservoir. Basic virus dynamics models of latency that do not take into account pyroptosis, superinfection, or other potential complexities cannot account for the data.Entities:
Mesh:
Year: 2017 PMID: 28630490 PMCID: PMC5476677 DOI: 10.1038/s41598-017-04130-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1(A) Basic properties of model (1). The death rate of infected cells, a, was varied (from a = 0.1d−1 to a = 1d−1), and the relationship between the equilibrium number of latently and productively infected cells was plotted. λ = 10 d−1, d = 0.015 d−1, a0 = 0.003 d−1, g = 0.001 d−1, β = 0.0057/(dayxcells), q = 0.95, f = 1/7. Higher values of the death rate parameter a can be thought of representing a CTL response that reduces the life-span of infected cells. (B) In vitro latency following infection of Jurkat T cells with fluorescent reporter viruses. Plotted is the calculated percentage of latently infected cells (those without a productive virus) among all cells that are singly, doubly, and triply infected. Details of data and calculations are given in the Supplementary Materials. The average from six replicas of the experiment was determined, and standard errors are shown. According to t-tests, the difference was significant comparing the average percentage among singly and doubly infected cells (p = 0.039), among singly and triply infected cells (p = 0.00049), and among doubly and triply infected cells (p = 0.032). (C) Acute infection dynamics, predicted by model (1). λ = 10 d−1, d = 0.015 d−1, a = 0.45 d−1, a0 = 0.003 d−1, g = 0.001 d−1, β = 0.0057/(dayxcells), q = 0.95, f = 1/7. (D) Data replotted from reference 24: As in the original paper, a straight line was fitted through these data (p = 0.04). Also, a polynomial function can be fit through these data, describing a one-humped relationship (p = 0.006). The linear model has a slightly lower Akaike information criterion (AIC) value than the polynomial model, with a difference of only Δ = 0.38. (E) Relationship between the number of latently infected cells and the area under the virus growth curve, according to stochastic Gillespie simulations[36] of model (1). For each realization of the simulation, parameters were chosen randomly from a uniform distribution, assuming a range of +/−10% of the base values. Each dot represents one realization. The time at which measures were determined was also randomly chosen in the range between 1 and 11 days. The base parameters are: λ = 100 d−1, d = 0.003 d−1, a = 0.45 d−1, a0 = 0.003 d−1, g = 0.001 d−1, β = 0.000114/(dayxcells), q = 0.95, f = 1/7. Parameters were adjusted compared to other figures to ensure persistence in the stochastic setting.
Figure 2Exploring the relative equilibrium abundance of productively (solid line) and latently infected (dashed line) cells in chronic infection models (2/3). The graphs plot the equilibrium cell populations as a function of the immune responsiveness parameter c. Model (2) without pyroptosis/superinfection is compared to model (3) with pyroptosis/superinfection of latently infected cells. (A) The models assume a non-lytic immune response. Parameters were chosen as follows: a = 0.45 d−1, a0 = 0.003 d−1, g = 0.001 d−1, β = 3.6/(dayxcells), q = 0.95, p1 = 1/(dayxcells) b = 0.1 d−1, f = 1/7. (B) The models assume a lytic immune response. Parameters were chosen as follows: a = 0.45 d−1, a0 = 0.003 d−1, g = 0.001 d−1, β = 3.6/(dayxcells), q = 0.95, p2 = 1/(dayxcells), b = 0.1 d−1, f = 1/7.
Figure 3Archiving of viral genomes in the agent-based model assuming a relatively weak immune response against the virus. Computer simulations with and without pyroptosis/superinfection of latently infected cells are compared. The simulation tracks the time when latent genomes are generated during the course of the in silico infection, and the graphs are frequency distributions of the creation times of all latent virus genomes that are present at 1000 days post infection (in the latent reservoir, i.e. in cells that do not contain productive virus). (A) It is assumed that the latent reservoir has a half-life of about 6 months[2]. Each time step of the simulation corresponds to 0.1 days, and the probabilities per time step are given as follows. A = 0.045, A0 = 0.0003, G = 0.0001, B = 0.36, H = 0.01. During infection, Q = 0.95 is the probability of productive infection. The probabilities of CTL proliferation and CTL-induced inhibition of virus replication are determined by parameters C = 0.5, and F = 0.1, respectively. (B) Same simulation, assuming that the latent reservoir has a half-life of about 31 months[3]. Parameters were the same, except A0 = 0.00006, G = 0.000015.
Figure 4Influence of a stronger immune response on the archiving of viral genomes. Computer simulation was the same as in Fig. 3, except for the two parameters C = 10 and F = 10, which simulate a stronger immune response.